Close
Close

Scynexis, Inc. - Mucocutaneous Candidiasis

Partner

Not provided

Rare Disease

Mucocutaneous Candidiasis

Sponsor

Scynexis, Inc.

Access Program Information

This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of SCY-078 in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment.

Contact

Contact: Silvia Helou, MD (201-884-5480)

Locations
  • United States
  • Augusta, Georgia, United States
  • United States
  • Chicago, Illinois, United States
  • United States
  • Saint Louis, Missouri, United States
  • United States
  • Durham, North Carolina, United States
  • United States
  • Pittsburgh, Pennsylvania, United States
  • United States
  • Houston, Texas, United States

Free Newsletter